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Abstract 
Background: Early stages of Alzheimer's disease (AD) are characterized by high 
phosphorylation of microtubule-associated protein tau, which may result from the 
downregulation of protein phosphatases.  
New method: In order to model phosphatase downregulation and analyze its effect on tau 
aggregation in vitro, we treated neuroblastoma SH-SY5Y cells with okadaic acid (OA), a 
protein phosphatase inhibitor, and examined high molecular weight phospho-tau species. 
Results and comparison with existing methods: OA treatment led to the appearance of heat-
stable protein species with apparent molecular weight around 100 kDa, which were 
immunoreactive to anti-tau antibodies against phosphorylated Ser202 and Ser396. As these 
high molecular weight tau-immunoreactive proteins (HMW-TIPs) corresponded to the 
predicted size of two tau monomers, we considered the possibility that they represent 
phosphorylation-induced tau oligomers. We attempted to dissociate HMW-TIPs by urea and 
guanidine, as well as by alkaline phosphatase treatment, but HMW-TIPs were stable under all 
conditions tested. These characteristics resemble properties of certain sodium dodecyl sulfate 
(SDS)-resistant tau oligomers from AD brains. The absence of HMW-TIPs detection by anti-
total tau antibodies Tau46, CP27 and Tau13 may be a consequence of epitope masking and 
protein truncation. Alternatively, HMW-TIPs may represent previously unreported 
phosphoproteins cross-reacting with tau. 
Conclusions: Taken together, our data provide a novel characterization of an OA-based cell 
culture model in which OA induces the appearance of HMW-TIPs. These findings have 
implications for further studies of tau under the conditions of protein phosphatase 
downregulation, aiming to explain mechanisms involved in early events leading to AD. 
 
 
Highlights 
 OA treatment of SH-SY5Y cells induced 100 kDa tau-immunoreactive species 
 Induced HMW species were reactive to anti-tau-pS202 and anti-tau-p396 antibodies  
 HMW species were heat-stable and stable in SDS, urea and guanidine  
 OA-induced HMW species could not be detected by several anti-total tau antibodies  
 HMW proteins may represent tau oligomers or phosphoproteins cross-reacting with tau  
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1. Introduction  
One of the neuropathological hallmarks of Alzheimer’s disease (AD) is the aggregation of tau 
protein in neurofibrillary tangles (NFT) in the neurons and glia cells in the brain. Tau 
(tubulin-associated unit) is a microtubule-associated protein, expressed mainly in neurons of 
the central nervous system [1], where its primary function is to modulate microtubule 
dynamics [2]. In adult human brain, there are six tau splicing isoforms ranging from 352 to 
441 amino acids (for review, see [3]). Isoforms differ by the absence or presence of one or 
two 29 amino acid inserts in the N-terminal part in combination with either three or four 
microtubule-binding (MTB) repeat regions in the C-terminal part (for review, see [4]).  
Tau is normally a natively unfolded protein [5] with little tendency for aggregation, therefore 
an intriguing, but mostly unresolved question is to understand what causes wild-type tau 
molecules to oligomerize and subsequently form larger aggregates that form NFT. Pathways 
leading to tau aggregation are largely unclear. However, tau propensity to aggregate may be 
driven by posttranslational modifications, mainly phosphorylation and C-terminal truncation 
[6]. Despite a paucity of stable secondary structure, tau in solution seems to form a transient 
global fold in which N- and C-terminal arms fold over the central MTB repeat domain that 
contains the sequences with a tendency to form -sheets and aggregate (known as the “paper 
clip” model [7]). 
Phosphorylation decreases affinity of tau for microtubules and makes it more prone to 
aggregation (for review, see [8]). In AD brains more than thirty tau amino acid residues are 
specifically phosphorylated, including Ser202 and Ser396 [9]. Hyperphosphorylation of tau in 
AD seems to be a consequence of a disrupted balance between kinase and phosphatase 
activity [10]. Several protein phosphatases were found dysregulated in AD brain, including 
PP2A, PP1 and PP5, which are all capable of dephosphorylating tau in vitro (for review, see 
[11]. The main regulator of tau dephosphorylation in healthy human brain appears to be 
PP2A, since its activity accounted for about 70% of the tau dephosphorylation in the assay 
using brain extracts [12]. PP2A has been shown to dephosphorylate tau in vitro at multiple 
sites, including Ser202 and Ser396 [13]. PP2A affects tau phosphorylation levels not only 
directly, but also indirectly by regulating the activities of several tau kinases, most notably 
glycogen synthase kinase 3β (GSK-3β) and Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) [14].  
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Studying the process of tau aggregation requires a suitable cell culture model. In this report 
we examined the potential of SH-SY5Y cell line treated with the phosphatase inhibitor 
okadaic acid (OA) as a model for studying the initial steps of tau aggregation. SH-SY5Y is a 
widely used human neuroblastoma cell line with an endogenous expression of tau and the 
capacity to differentiate into neuron-like cells [15-17]. Okadaic acid is a cell-permeable potent 
inhibitor of protein phosphatases PP2A, PP4, PP5 and PP1 [18, 19], which has been 
previously used to upregulate the levels of phospho-tau in cultured cells and to investigate the 
role of protein phosphatases in tau phosphorylation [20-24]. To investigate the potential of 
SH-SY5Y cells treated with protein phosphatase inhibitor OA as a model for studying the 
process of tau aggregation and neurodegeneration [25], we examined the effects of OA 
treatment on generation of high molecular weight tau. We observed that the incubation of SH-
SY5Y cells with OA leads to the expression of a high molecular weight phospho-protein 
species immunoreactive to tau antibodies against phosphorylated Ser202 and phosphorylated 
Ser396.  
 
4. Materials and Methods 
 
4.1. Cell culture  
Cells SH-SY5Y (ECACC, 94030304) were grown in Dulbecco’s modified Eagle medium 
(DMEM, Gibco, Gaithersburg, MD, USA, cat. no. 31885-049) supplemented with 10% fetal 
bovine serum (FBS, Gibco, cat. no. 10270106), 1% L-glutamine (Gibco, cat. no. 25030024), 
1% non-essential amino acids (Sigma-Aldrich, Darmstadt, Germany, cat. no. M7145) and 1% 
penicillin-streptomycin (Gibco, cat. no. 15140-122) at 37°C in humidified atmosphere with 
5% CO2. Unless indicated otherwise, undifferentiated SH-SY5Y cells grown to 60-90% 
confluency were used. For differentiation into neuron-like type, we followed the protocol 
described by Encinas and colleagues [26] with minor modifications. Briefly, cells were 
seeded at density of 10,000 cells/cm2 in the medium described above. The following day a 
medium containing 10 M all-trans retinoic acid was added to the cells and incubated for five 
days, the medium being replaced every other day. Cells were washed with serum-free medium 
and incubated in medium containing 1% FBS and 50 ng/ml brain-derived neurotrophic factor 
(BDNF, Sigma-Aldrich, cat. no. SRP3014) for two days. Cells were photographed using 
phase contrast microscopy (Zeiss, Oberkochen, Germany). Where indicated, cells were 
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treated with indicated concentration of OA (Abcam, Cambridge, UK, cat. no. ab120375) 
added from 100 M OA solution in dimethyl sulfoxide (DMSO). As a negative control, an 
equal amount of DMSO to the one used in OA solution was applied to the cells.   
 
4.2. Testing cell viability by MTT assay  
Cell viability was tested using MTT assay. In short, cells were grown in 96-well plates 
containing 100 l cell culture medium and treated with 30 nM OA, added from a 100 M OA 
solution in DMSO. For control, an equal amount of DMSO as used in OA solution was added 
to cells. After 8 h, 40 µl of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) was added to each well and samples were incubated at 37°C for 3 h, followed by the 
addition of 160 µl of DMSO. Absorbance at 570 nM was measured using BioRad XR680 
microplate reader (BioRad Laboratories, Hercules, CA, USA). 
 
4.3. Preparation of cell lysates and protein extraction  
Upon harvesting, cells were washed in ice-cold Tris-buffered saline (TBS) buffer (20 mM 
Tris-HCl pH 7.4, 150 mM NaCl) and resuspended in Laemmli buffer (50 mM Tris-HCl pH 
6.8, 2% sodium dodecyl sulfate [SDS], 2 mM ethylenediaminetetraacetic acid [EDTA], 10% 
glycerol, 1 “Complete Mini” protease inhibitor cocktail tablet per 10 ml [Roche Diagnostics, 
Basel, Switzerland cat. no. 11836170001, Roche Diagnostics, Basel, Switzerland], 1 mM 
phenylmethylsulfonyl fluoride [added from a 100x concentrated solution in DMSO], 10 mM 
sodium fluoride, 20 mM -glycerophosphate, and 2 mM sodium orthovanadate). For 
experiments shown in Figures 1E, 2B, and 3A cells were resuspended in 2x Laemmli buffer 
without prior washing step. -mercaptoethanol (2-5%) was present in the lysis buffer and 
samples were denatured at 90°C or 95°C for 5-15 min. For the experiment shown in Figures 
1A, 1B, 3D, and S1 cells were resuspended in ice-cold radioimmunoprecipitation assay 
(RIPA) buffer (20 mM Tris-HCl pH 7.4, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 
0.5% sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 10% glycerol, protease and 
phosphatase inhibitors as described above), drawn through 23 G needle 8 times and incubated 
on ice for 30 min. Samples were centrifuged at 20,000 g for 10 min at 4°C, supernatant was 
collected, mixed with Laemmli buffer containing 5% -mercaptoethanol and incubated at 
95°C for 5 min. For the experiment in Fig. S1, prior to adding Laemmli buffer, samples were 
incubated at 85°C for 10 min and centrifuged at 20,000 g for 10 min. For urea treatment, cells 
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were resuspended in 2x Laemmli buffer containing 8 M urea, samples were incubated at 65°C 
for 10 min, centrifuged at 20,000 g for 20 min at room temperature (RT) and the supernatant 
was collected. 
 
4.4. Cell extraction by guanidine-hydrochloride 
Cells harvested by trypsinization were washed in ice-cold phosphate-buffered saline (PBS) 
and resuspended in a solution containing 6 M guanidine-hydrochloride, 20 mM Tris-HCl pH 
7.4 and 100 mM NaCl, incubated at RT for 10 min. Suspension was drawn through 23 G 
needle and incubated at RT for 20 min, followed by centrifugation at 20,000 g for 5 min at 
4°C (Fig. S3B) or 20 min at RT (Fig. 5B). The supernatant was collected and the 
centrifugation step repeated. Guanidine hydrochloride forms a precipitate with SDS and is 
thus incompatible with SDS-PAGE [27]. To remove guanidine hydrochloride, proteins from 
the supernatant were precipitated by incubation in 90% ethanol at -20°C for 1 h. The samples 
were centrifuged at 20,000 g for 10 or 20 min at 4°C, the pellet was washed in absolute 
ethanol and air-dried. For the experiment shown in Fig. 5B, precipitated proteins were 
solubilized in 2x Laemmli buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 4 mM EDTA, 10% 
glycerol, 1 Roche “Complete Mini” protease inhibitor cocktail tablet per 10 ml, 1 mM 
phenylmethylsulfonyl fluoride, 10 mM sodium fluoride, 20 mM -glycerophosphate and 2 
mM sodium orthovanadate) containing 8 M urea, incubated at 37°C for 20 min, and 
centrifuged at 20,000 g for 20 min at RT. -mercaptoethanol was added to supernatant to a 
final concentration of 5 % and the centrifugation step repeated. For the experiment shown in 
Fig. S3B, precipitated proteins were solubilized in a volume of RIPA buffer, followed by the 
addition of a third of the volume of concentrated Laemmli buffer containing 5% -
mercaptoethanol, incubation at 95°C for 5 min, centrifugation at 20,000 g at RT and the 
collection of the supernatant.  
 
4.5. Heat-stable protein fraction 
To prepare heat stable fraction, we followed the protocol described by Petry et al. with some 
modifications [28]. Briefly, the cells harvested by Versene (Gibco, cat. no. 15040-066) were 
resuspended in 300 l lysis buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 0.25 % 
sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1 Roche “Complete Mini” 
protease inhibitor cocktail tablet per 10 ml, 1 mM phenylmethylsulfonyl fluoride, 10 mM 
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sodium fluoride, 20 mM -glycerophosphate, and 2 mM sodium orthovanadate), incubated on 
ice for 10 min, drawn through 23 G needle eight times, incubated on ice for 20 min and 
centrifuged at 20,000 g for 20 min at 4°C. The supernatant was collected and incubated at 
95°C for 10 min, followed by centrifugation at 20,000 g for 10 min at 4°C. Supernatant 
containing the heat-stable fraction (protein concentration of 0.4 - 0.5 g/l) was separated 
from the pellet. A volume of the heat-stable fraction (150 - 200 l) was incubated with one 
third of the volume of concentrated Laemmli buffer (8% SDS, 200 mM Tris-HCl pH 6.8, 8 
mM EDTA, 20% glycerol). The amount of the heat stable protein samples loaded on gel was 
12 g of protein. The pellet was resuspended in a similar volume of radioimmunoprecipitation 
assay (RIPA) buffer and concentrated Laemmli buffer.  
 
4.6. Alkaline phosphatase treatment of protein lysates 
The cells were treated with 100 nM OA for 2 h, trypsinized, washed in PBS buffer and 
resuspended in lysis buffer (50 mM Tris-HCl pH 7.9, 1% Triton X-100, 0.25% sodium-
deoxycholate, 150 mM NaCl, 1 mM MgCl2, 1 Roche “Complete Mini” protease inhibitor 
cocktail tablet per 10 ml, 1 mM phenylmethylsulfonyl fluoride, 10 mM sodium fluoride, 20 
mM -glycerophosphate), incubated on ice for 10 min, drawn through 23 G needle eight 
times, incubated on ice for 20 min followed by 5 min centrifugation at 20,000 g at 4°C and 
the supernatant (protein concentration of 0.4 g/l) was collected. To enrich heat stable 
proteins, the sample was incubated at 95°C for 10 min, followed by centrifugation at 20,000 g 
for 20 min at 4°C. The supernatant (10 l) was incubated with 10 U of alkaline phosphatase 
(Promega, Fitchburg, WI, USA, cat. no. M2825) or water (control) at 37°C for 30 min, 
followed by addition of Laemmli buffer and 5 min incubation at 95°C. The whole reaction 
mixture was loaded on gel for analysis by immunoblot.  
 
4.7. Immunoblotting 
Proteins in cell extracts were separated on 7.5% (Figures 1E, 3C, and 6) or 10% (all other 
figures) SDS-PAGE gels and transferred onto a nitrocellulose membrane in the transfer buffer 
(25 mM Tris, 192 mM glycine), using the voltage of 50 V for the duration of 2 h. The 
membrane was blocked in 5% milk diluted in TBS or phosphate-buffered saline (PBS; 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and incubated with primary 
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antibody diluted in TBS or PBS containing 5% milk or 3% bovine serum albumin, overnight 
at 4°C. The primary antibodies and their working dilutions used were: anti-tau-pS396 
(Abcam, cat. no. ab109390, 1:10,000 dilution), Tau46 (Sigma-Aldrich, cat. no. T9450, 
dilution 1:1,000), anti-tau-pS202 (CP13, mouse monoclonal, gift of Prof. Peter Davies, 
dilution 1:500), anti-total tau mouse monoclonal antibody CP27 (gift of Prof. Peter Davies, 
dilution 1:250), Tau13 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, cat. no. sc-21796, 
dilution 1:250), polyclonal anti-tau (DAKO-Agilent, CA, USA, cat. no. A-0024, dilution 
1:10000), anti-MAP2 (clone HM-2, Sigma-Aldrich, cat. no. M4403, dilution 1:1000), DC11 
(generous gift from dr. Michal Novak, dilution 1:50), anti--actin (Sigma-Aldrich, cat. no. 
A5441, dilution 1:10,000), and anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase, 
Cell Signaling, Leiden, Netherlands, cat. no. 2118, dilution 1:1,000 to 1:2,000). The 
secondary antibodies were horse radish peroxidase-linked IgG (Cell Signaling, cat. no. 7074 
and 7076). Proteins were visualized using Super Signal West substrate (Thermo Scientific, 
Waltham, MA, USA, Pico cat. no. 34077 or Femto cat. no. 34095) and imager ChemiDoc 
XRS+ with ImageLab software (BioRad Laboratories, Hercules, CA, USA). Exposure times 
were selected to maximize the signal to noise ratio. In the Fig. 1E, where the signal of 
samples present on two separate pieces of membrane is compared, membranes were imaged 
simultaneously. In Fig. 4, heat-stable fraction and pellet samples were present and analyzed 
on the same membrane and imaged simultaneously. Where appropriate, equal loading of 
samples on gel was assessed using GAPDH levels. Figures are showing representative images 
of data that were generated from at least three independent samples, or two independent 
experiments performed on different days, each containing two independent samples generated 
from separate cell culture dishes, treatment, harvesting and protein preparation. Where 
appropriate, data were analyzed using ImageLab software (BioRad Laboratories, Hercules, 
CA, USA).  
 
 
2. Results  
2.1. OA treatment of SH-SY5Y cells induced expression of 100 kDa proteins immunoreactive 
with anti-tau-pS202 and anti-tau-pS396 antibodies   
To inhibit the activity of protein phosphatases, we incubated undifferentiated neuroblastoma 
SH-SY5Y cells that endogenously express tau with OA. Taking into consideration the OA 
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concentration necessary to inhibit the activity of different tau protein phosphatases and 
possible high local concentration of phosphatases in the cultures [18], we initially treated the 
cells with 100 nM OA (Fig. 1A and 1B). A similar concentration had been used in previous 
studies [29-31]. Proteins from total cell protein lysates were separated by denaturing SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). Tau phosphorylation at specific epitopes 
was assessed by immunoblot using phospho-specific tau antibodies. Using the antibody that 
recognizes tau phosphorylated at S396, we observed protein bands of the apparent molecular 
weight of 50-65 kDa in samples from both treated (OA+) and untreated (OA-) cells (Fig. 1A). 
Additionally, a protein co-migrating with the molecular weight of ~100 kDa appeared in 
samples from cells treated with OA. The same samples were analyzed with the antibody CP13 
that recognizes tau phosphorylated at S202 (Fig. 1B). In cells treated with OA a protein with 
an apparent molecular weight of ~100 kDa was clearly visible, while in samples from 
untreated cells the signal was very weak or not detectable, indicating that under normal 
growth conditions endogenous tau is phosphorylated at S202 at low levels. The 100 kDa 
phospho-tau immunoreactive proteins were also induced upon cell treatment with lower OA 
concentrations of 30 nM OA for 8 h (Fig. 1C) and with 20 nM OA for 4 h (Fig. S1). Notably, 
MTT assay on cells treated with 30 nM OA for 8 h revealed that the viability of OA-treated 
cells was similar to control cells (Fig. 1D), suggesting that the appearance of 100 kDa protein 
is not due to OA-induced cell toxicity. Furthermore, a similar pattern of OA-induced 100 kDa 
phospho-tau immunoreactive protein was observed in SH-SY5Y cells differentiated into 
neuron-like cells (Fig. 2). Together, the data indicated that protein phosphatase inhibition by 
OA induced the formation of 100 kDa protein species immunoreactive to tau-pS202 and tau-
pS396. Based on the molecular size of the reported protein and its immunoreactivity with 
anti-tau antibodies, this result is consistent with the possibility of tau oligomerization.  
This high molecular weight tau-immunoreactive protein species (HMW-TIPs) detected with 
CP13 and anti-tau-S396 antibodies migrated in the SDS-PAGE with nearly identical 
electrophoretic mobility. To test whether both CP13 and anti-tau-pS396 recognized the same 
protein, we divided the lane containing protein lysate from OA-treated cells on the 
nitrocellulose membrane in half by cutting it vertically. We incubated one half with antibody 
CP13 and the other half with antibody against tau-pS396 and aligned the halves for imaging 
(Fig. 1E). We noticed that the protein band recognized by the CP13 antibody migrated 
slightly slower than the anti-tau-pS396 antibody-reactive band (Fig. 1E), indicating two 
distinct protein species. These distinct protein bands could represent an identical tau splicing 
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isoform containing different phosphorylation patterns or an additional posttranslational 
modification, such as protein truncation.  
Next, we examined HMW-TIPs using anti-total tau antibodies that recognize tau regardless of 
its phosphorylation state. We analyzed OA-treated and -untreated samples using antibody 
Tau46 that recognizes an epitope in the C-terminal part of tau (aa 404-441). We observed that 
antibody Tau46 does not detect the 100 kDa protein, although it recognizes 50 kDa tau and a 
protein around 70 kDa (Fig. 3A and Fig. 2B), which presumably represents a low molecular 
weight MAP2 isoform [32]. To test whether the 70 kDa protein recognized by antibody Tau46 
is a MAP2 isoform, we analyzed OA-treated samples with an anti-MAP2 antibody that 
detects all MAP2 isoforms (Fig. S2). In agreement with a previous report showing that SH-
SY5Y cells primarily express a 70 kDa MAP2 isoform [33], the anti-MAP2 antibody 
recognized a protein of this size, similarly to Tau46. The 70 kDa band was clearly distinct 
from the 100 kDa protein visualized with antibody CP13 (Fig. S2, left panel). 
Next, we used anti-total tau antibodies raised against other tau regions, Tau13 (epitope most 
likely within the first 35 aa), CP27 (whose epitope includes residues 130-150), and a rabbit 
polyclonal antibody raised against the C-terminal part of tau (aa 243-441). Despite the 
recognition of monomeric tau proteins, Tau13, CP27 and this polyclonal antibody did not 
detect HMW-TIPs (Fig. 3B-D). We further tested the reactivity of HMW-TIPs with antibody 
DC11 that has been reported to recognize truncated tau (aa 151-421) [34]. However, the 
pattern of DC11 antibody did not overlap with that of HMW-TIPs (Fig. 3E). 
Taken together, we were unable to detect HMW-TIPs using several anti-total tau antibodies, 
which together cover tau epitopes in the N-terminal, central and C-terminal regions of tau, 
and additionally an antibody against a truncated version of tau. The lack of HMW-TIPs 
detection using these antibodies could be due to antigen masking within the oligomer or a 
combination of epitope masking and a different tau protein truncation. 
 
2.2. HMW-TIPs are found in a heat-stable fraction 
To investigate the properties of HMW-TIPs, we examined whether it could be found in a 
heat-stable fraction. Due to their internally disordered structure, tau and other MAP2 family 
proteins are resistant to heat-induced precipitation. After isolating a heat-stable fraction using 
the protocol described by Petry and collaborators [28], in which cells are lysed in a buffer 
containing 1% non-ionic detergent Triton X-100, 0.25% ionic detergent sodium-deoxycholate 
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and 150 mM NaCl, but no SDS, the cell lysate was boiled and insoluble proteins were 
precipitated by centrifugation at 20,000 g. As expected, antibody Tau46 detected 50 kDa tau 
and a 70 kDa protein, presumably a MAP2 isoform [32] in the heat-stable fraction, and no 
signal was observed in the pellet fraction (Fig. 4A, upper panels). In contrast, the levels of -
actin were much lower in the heat-stable fraction than in the pellet (Fig. 4A, lower panels). 
Together, this indicated that the heat-stable fraction was enriched in heat-stable proteins. 
Using the antibodies anti-tau-pS396 and CP13, we found that HMW-TIPs were present in the 
heat-stable fraction (Fig. 4B). In conclusion, HMW-TIPs co-fractionated with heat-stable 
Tau46-reactive proteins, which is a characteristic of proteins with internally disordered 
structure, including tau.  
 
2.3. HMW-TIPs are stable under reducing and strong denaturing conditions  
Considering the possibility that HMW-TIPs represent tau oligomers, we tested conditions 
under which oligomers could be dissociated. Previous reports have shown that tau oligomers 
can be disrupted under reducing conditions [35,36], although tau crosslinking by disulfide 
bonds is not an absolute prerequisite for tau aggregation. Cell lysates in all the experiments 
were prepared under reducing conditions, therefore this indicated that the stability of the 
putative oligomer does not depend on disulfide bonds. Next, we examined whether putative 
oligomers could be dissociated by strong denaturing agent urea and guanidine hydrochloride.  
Immunoblot analysis of cell lysates using CP13 antibody revealed that HMW-TIPs did not 
dissociate in the presence of either 8 M urea (Fig. 5A) or 6 M guanidine hydrochloride (Fig. 
5B), and a similar result was obtained using anti-tau-pS396 antibody (Fig. S3). Quantification 
of HMW-TIPs signal relative to GAPDH levels in samples prepared with and without 8 M 
urea revealed that there was no significant difference between anti-tau-pS396-reactive HMW-
TIPs levels in samples from OA-treated cells extracted with and without urea (Fig. S3A), 
while the levels of CP13-immunoreactive HMW-TIPs were higher in cell lysates prepared 
with urea than without urea, presumably due to a better extraction in the presence of urea 
(Fig. 5A).  
 
2.4. Characterization of the HMW-TIPs species upon protein dephosphorylation  
Finally, to examine the impact of protein phosphorylation on the putative 100 kDa tau 
oligomer, lysates of cells treated with OA were incubated with alkaline phosphatase. Because 
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none of the tested anti-total tau antibodies recognized HMW-TIPs, this presented an obstacle 
in examining proteins upon dephosphorylation. Surprisingly, we observed that alkaline 
phosphatase treatment did not abolish detection of 55-60 kDa tau and HMW-TIPs by anti-tau-
pS396 antibody (Fig. 6), although their electrophoretic mobility was slightly modified (Fig. 6, 
compare molecular weight of proteins in the samples treated and not treated with alkaline 
phosphatase). The change in electrophoretic mobility indicates that some amino acid residues 
were dephosphorylated, but not the S396 epitope. Under similar conditions of alkaline 
phosphatase treatment, CP13-dependent signal of HMW-TIPs was diminished (Fig. S4), 
indicating efficient dephosphorylation at the tau-S202 epitope. The fact that alkaline 
phosphatase treatment affects the migration rate of HMW-TIPs only to a small degree 
suggested that the putative oligomer does not dissociate into monomers upon partial protein 
dephosphorylation.  
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3. Discussion 
We used SH-SY5Y cell culture model of protein phosphatase downregulation based on cell 
treatment with OA and showed that OA leads to the appearance of 100 kDa protein species 
immunoreactive to phospho-tau specific antibodies CP13 (anti-tau-pS202) and anti-tau-
pS396.  
Based on its molecular size, we initially considered the possibility that HMW-TIPs represent 
large tau splicing isoform containing exon 4A (so-called “big tau”), which contains an 
additional 254 aa insert in the N-terminal part [37] and is normally expressed predominantly 
in the peripheral nervous tissue [38]. This would be in accordance with a previous report 
showing that SH-SY5Y cells and their parental line SK-N-SH express a tau isoform around 
100 kDa [16]. However, we were unable to detect HMW-TIPs using any of the antibodies 
used against total tau, namely Tau46, CP27, Tau13, and a rabbit polyclonal antibody. As “big 
tau” normally contains all of the epitopes recognized by these antibodies, with the possible 
exception of CP27, and these epitopes are not recognized by the anti-total tau antibodies we 
used, it is highly unlikely that HMW-TIPs represent “big tau”.  
Based on the observation that the molecular weight of the HMW-TIPs corresponds to the 
predicted size of two molecules of fetal tau, which is one of the most prominent tau isoforms 
in undifferentiated SH-SY5Y cells [17], we considered the possibility that it represents tau 
oligomers. In support of this possibility, a study using bimolecular fluorescence 
complementation showed that HEK293 cells expressing tau constructs fused to split Venus 
increase in fluorescence upon treatment of cells with 30 nM OA for 24 h, suggesting tau 
oligomerization [39]. The absence of oligomer detection by anti-total tau antibodies in our 
experiments could be a consequence of by epitope masking or a combination of epitope 
masking and protein truncation, which would render HMW-TIPs unrecognizable. 
In attempt to dissociate putative oligomers by reducing and denaturing agents, we found that 
HMW-TIPs were stable in the presence of -mercaptoethanol, SDS, urea and guanidine. The 
role of disulfide bridges in tau oligomerization is not entirely clear, as both reduction-
sensitive and reduction-resistant tau dimers have been previously observed [35, 36]. In our 
experiments, HMW-TIPs were detected in the presence of -mercaptoethanol, indicating that 
the stability of a putative oligomer does not depend on disulfide bonds. Despite the fact that 
most protein complexes dissociate in the presence of SDS, some protein complexes remain 
assembled [40]. For example, SDS-resistant tau oligomers have been reported in AD brain 
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[35]. Moreover, it has been previously reported that a pool of tau isolated from AD brain 
remained aggregated in high molecular mass structures even after the treatment with 8 M urea 
[41], whereas certain types of tau aggregates were stable in 6 M guanidine hydrochloride [42]. 
Taken together, we were unable to dissociate putative oligomers with SDS, urea, and 
guanidine. However, the observed stability of HMW-TIPs in the presence of these agents is 
compatible with the characteristics of some previously reported tau oligomers.  
The present study showed that treatment of cell lysates with alkaline phosphatase resulted in 
partially dephosphorylated HMW-TIPs, leaving the S396 epitope phosphorylated and the 
putative oligomer assembled. In fact, an inefficient removal of phosphates by alkaline 
phosphatase from the tau PHF-1 epitope, which includes pS396 and pS404, has been already 
reported [43]. Our data suggest that exhaustive tau phosphorylation is either not essential for 
the stability of the putative oligomer, or is necessary for initial oligomer formation, but once 
formed, oligomers could be stable even upon dephosphorylation. Based on our present data it 
is also possible that, in addition to other sites, dephosphorylation of S396 is required for the 
disassembly of the putative oligomer.  
Finally, OA affects several cellular processes [45] and inhibition of protein phosphatases PP1, 
PP2A, PP4 and PP5 by OA is lethal to most human cells [18]. To minimize the toxic effect of 
OA on cells, we used treatment with OA concentrations of 100-150 nM for a short period of 
2-2.5 h. Moreover, we have also observed the induction of the 100 kDa anti-tau reactive 
protein using a lower OA concentration of 20 nM for 4 h and upon cell treatment with 30 nM 
OA for 8 h, which did not affect cell viability, suggesting that the appearance of the 100 kDa 
protein is not due to OA-induced cell toxicity. However, we cannot entirely exclude the 
possibility that OA-induced HMW-TIPs is not a direct consequence of tau-immunoreactive 
protein phosphorylation, but could arise due to an indirect effect of phosphatase inhibition by 
OA [44], or through a phosphatase-independent pathway [45]. 
In summary, OA treatment of SH-SY5Y cells lead to the appearance of HMW proteins 
immunoreactive to anti-tau-pS202 and -pS396 antibodies, which is in line with the possibility 
that HMW-TIPs represent tau oligomers. However, due to the inability to detect HMW-TIPs 
with anti-total tau antibodies and to dissociate putative oligomers under conditions tested, we 
cannot exclude the possibility that HMW-TIPs represent tau-unrelated proteins that are 
detected with anti-tau-pS202 and -pS396 antibodies due to cross-reactivity. The finding that 
anti-tau-pS396- and -pS202-immunoreactive HMW-TIPs exhibited almost identical, yet 
distinct electrophoretic mobilities in SDS-PAGE supports this possibility. Furthermore, 
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although HMW-TIPs were present in the heat-stable fraction, which is a characteristic of tau 
and other intrinsically disordered proteins [46], it should be noted that due to the presence of 
1% Triton X-100 and 0.25% sodium-deoxycholate in the lysis buffer, our protocol may have 
extracted a broader range of proteins than buffers without detergents.  
In conclusion, we provide strong evidence that OA treatment of neuroblastoma cells in culture 
induces a high molecular weight phospho-tau immunoreactive species. Although additional 
research is required to clarify further the identity of the reported proteins, our findings 
indicate that OA-treated SH-SY5Y cells represent a potentially valuable cell culture model for 
studying tau oligomerization under the conditions of protein phosphatase downregulation, as 
well as tau aggregation inhibitors and neuroprotective compounds [47-49]. Our findings may 
thus facilitate future studies aiming to explain molecular mechanisms involved in the early 
events leading to tau aggregation and neurodegeneration, which may eventually lead to 
effective therapy and prevention of neurofibrillary degeneration and AD.  
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Abbreviations 
 
AD   Alzheimer’s disease 
BDNF   brain-derived neurotrophic factor 
CP13   antibody against phosphorylated tau Ser-202  
CP27   antibody against total tau (aa 130-150) 
DMEM  Dulbecco’s modified Eagle medium 
DMSO  dimethyl sulfoxide 
EDTA   ethylenediaminetetraacetic acid 
FBS   fetal bovine serum 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GSK-3β  glycogen synthase kinase 3β 
HMW-TIPs  high molecular weight tau-immunoreactive proteins 
HS   heat-stable (fraction) 
MAP   microtubule-associated protein 
MTB   microtubule binding (repeat regions) 
NFT   neurofibrillary tangles 
OA    okadaic acid 
PBS   phosphate-buffered saline 
PP2A   protein phosphatase 2A 
RIPA   radioimmunoprecipitation assay buffer 
SDS-PAGE  sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
Tau13   antibody against the N-terminal part of tau (aa 2-18) 
Tau46   antibody against the C-terminal part of tau (aa 404-441) 
TBS   Tris-buffered saline 
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FIGURES AND FIGURES LEGENDS  
 
Figure 1. OA treatment of SH-SY5Y cells induces expression of a high molecular weight 
protein species immunoreactive to phospho-tau. Undifferentiated SH-SY5Y cells were 
treated with indicated concentrations of OA for an indicated time period. Around 25 g 
protein in total cells lysates were analyzed by immunoblotting using antibodies that detect 
tau-pS396 or tau-pS202 (CP13). GAPDH served as a loading control (A-C). Note a strong 
band migrating around 100-kDa in lysates of OA-treated cells (A-C). (D) Viability of cells 
treated with 30 nM OA for 8 h (number of independent samples n = 8) and control cells (n = 
4) was tested using MTT assay. Percent viability of control cells is shown. No significant 
difference in viability was found (t = 0.372, df = 10, p = 0.125). (E) Nitrocellulose membrane 
with transferred proteins was cut vertically in the middle of the lane (scissors) and the halves 
were incubated with CP13 or anti-tau-pS396 antibodies. Membranes were placed side-by-side 
and imaged simultaneously. 
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Figure 2. HMW-TIP is detected in OA-treated SH-SY5Y cells differentiated into 
neuron-like cells. Differentiated SH-SY5Y cells visualized using phase contrast microscopy 
(A) were treated with 100 nM OA for two hours. Note the differentiated cells with visible 
neuritic processes. Scale bar = 50 m. Total cell lysates were analyzed by immunoblot using 
anti-tau-pS202 (CP13), anti-tau-pS396 and anti-total tau (Tau46) antibodies (B). Note a 
strong band migrating around 100-kDa in lysates of OA-treated cells. GAPDH is used as a 
loading control.   
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Figure 3. HMW-TIPs are not detected by anti-total tau antibodies. Where indicated, cells 
were treated with 100 nM (A, D) or 150 nM (B, C, E) OA for 2 - 2.5 hours. Total cell lysates 
were analyzed by immunoblotting using anti-total tau antibodies Tau46 (A), CP27 (B), Tau13 
(C) and rabbit polyclonal antibody (D), and antibody DC11 against truncated tau (E). To 
visualize HMW-TIPs, same samples were analyzed by antibody CP13 (A-C) or anti-tau-
pS396 (D, E). Note a CP13- and anti-tau-pS396- reactive band migrating around 100-kDa in 
lysates of OA-treated cells (A-E). Note that all anti-total antibodies detect a band migrating 
above 50 kDa that represents monomeric tau, but do not detect 100 kDa protein (A-D). Tau46 
antibody additionally detects a 70 kDa band that presumably represents MAP2 isoform (A). 
GAPDH served as a loading control (C, D). Control and OA-treated samples in (D) were 
present on the same membrane. Note that the rabbit polyclonal anti-total antibody (right 
panel) detects a band migrating above 100 kDa tau (red arrow), which is clearly distinct from 
the OA-induced anti-tau-pS396-reactive band (left panel, OA+) migrating at 100 kDa (black 
arrow).   
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Figure 4. HMW-TIP is present in a heat-stable fraction. SH-SY5Y cells were treated with 
100 nM (OA+) or DMSO (OA-) for 2:15 h. (A) Heat-stable (HS) and pellet fractions were 
analyzed by immunoblot using anti-total tau antibody Tau46 (upper panels) and anti--actin 
(lower panels). Heat-stable fraction and pellet samples were analyzed on the same 
nitrocellulose membrane and imaged simultaneously. Note that 50 kDa tau and 70 kDa 
proteins (70 kDa protein presumably being a MAP2 isoform) detected by Tau46 antibody are 
enriched in the heat-stable fraction compared to the pellet. In contrast, -actin is enriched in 
the pellet compared to heat-stable fraction. (B) The same samples of heat-stable (HS) fraction 
as in (A) were analyzed by immunoblot using anti-tau-pS396 and CP13 (anti-tau-pS202) 
antibodies. Note the presence of pS396- and CP13-immunoreactive 100 kDa bands in the heat 
stable fraction.  
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Figure 5. HMW-TIP is stable under denaturing conditions. Cells were treated with 150 
nM (A) or 100 nM (B) OA for 2 h. Cell lysates were prepared in the absence or presence of 8 
M urea (A) or with 6 M guanidine-hydrochloride (B). Immunoblotting was performed using 
anti-tau-pS202 antibody (CP13). GAPDH was used as a loading control. Note that the 100 
kDa band is present in samples from OA-treated cells under all tested conditions. The graph 
shows signal intensity of HMW-TIP relative to GAPDH levels of the samples shown in A. 
Average values and standard deviation of replicate samples are shown.  
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Figure 6. HMW-TIPs stability upon protein dephosphorylation. Cells were incubated 
with 100 nM OA for 2 h. Heat-stable fraction was treated with alkaline phosphatase (AP) 
where indicated and analyzed by immunoblot using anti-tau-pS396 antibody. Note the 
persistent antibody detection of protein migrating around 100 kDa and changed 
electrophoretic mobility of proteins treated with alkaline phosphatase.  
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Figure S1. Treatment of SH-SY5Y cells with low concentration of OA induces 
expression of 100 kDa tau-reactive protein. Cells were treated with 20 nM OA for 4 h. 
Samples were analyzed by immunoblotting using antibodies that detect tau-pS202 (CP13 
antibody, upper panel) and tau-pS396 (lower panel). Note CP13- and pS396-immunoreactive 
bands (arrows) migrating around 100-kDa in lysates of OA-treated cells. 
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Figure S2. Anti-MAP antibody detects 70 kDa protein reactive to Tau46. Cells were 
treated with 150 nM OA for 2 h and total cell lysates were analyzed by immunoblot using 
antibodies CP13, anti-MAP2 and Tau46. GAPDH was used as a loading control. Arrows 
mark the 100 kDa tau-reactive protein. Asterisk marks anti-MAP2- and Tau46-
immunoreactive protein migrating at 70 kDa.  
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Figure S3. Anti-tau-pS396-immunoreactive HMW-TIP is stable under denaturing 
conditions. Cells were treated with 150 nM (A) or 100 nM (B) OA for 2 h. Cell lysates were 
prepared in the absence or presence of 8 M urea (A) or using lysis buffer containing 6 M 
guanidine-hydrochloride (B). Immunoblotting was performed using anti-tau-pS396 antibody. 
GAPDH was used as a loading control. Note that the 100 kDa band is present in samples from 
OA-treated cells under all tested conditions. The graph shows signal intensity of anti-tau-
pS396 reactive HMW-TIP relative to GAPDH levels of the samples shown in A. Average 
values and standard deviation of replicate samples are shown. Note that there is no significant 
difference between “+OA -urea” and “+OA +urea” conditions (p = 0.34).  
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Figure S4. CP13-dependent HMW-TIPs signal diminishes upon protein 
dephosphorylation by alkaline phosphatase. Cells were incubated with 100 nM OA for 2 h. 
Heat-stable fraction was treated with alkaline phosphatase (AP) and analyzed by immunoblot 
using CP13 antibody. Note the 100 kDa band representing HMW-TIPs and the disappearance 
of the signal upon alkaline phosphatase treatment.  
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